Literature DB >> 12570846

Opioid ligands having delayed long-term antagonist activity: potential pharmacotherapies for opioid abuse.

Stephen M Husbands1, John W Lewis.   

Abstract

Buprenorphine is a partial agonist at the micro -opioid receptor with long duration of action and also exhibits delayed antagonist activity. Buprenorphine is finding increasing use as a treatment agent for opioid abuse, though its low efficacy is not well tolerated by all addicts. There is interest in developing a higher efficacy version of buprenorphine and in this mini-review some of the ligands recently discovered, that share with buprenorphine a profile of agonism followed by delayed antagonism, are discussed.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12570846     DOI： 10.2174/1389557033405395

Source DB:  PubMed          Journal:  Mini Rev Med Chem        ISSN： 1389-5575            Impact factor:   3.862


  9 in total

1.  14beta-Arylpropiolylamino-17-cyclopropylmethyl-7,8-dihydronormorphinones and related opioids. Further examples of pseudoirreversible mu opioid receptor antagonists.

Authors:  Nick P R Nieland; David Rennison; Jillian H Broadbear; Lauren Purington; James H Woods; John R Traynor; John W Lewis; Stephen M Husbands
Journal:  J Med Chem       Date:  2009-11-12       Impact factor: 7.446

2.  Structural determinants of opioid activity in derivatives of 14-aminomorphinones: effect of substitution in the aromatic ring of cinnamoylaminomorphinones and codeinones.

Authors:  Nick P R Nieland; Humphrey A Moynihan; Simon Carrington; Jillian Broadbear; James H Woods; John R Traynor; Stephen M Husbands; John W Lewis
Journal:  J Med Chem       Date:  2006-08-24       Impact factor: 7.446

Review 3.  Most recent developments and modifications of 14-alkylamino and 14-alkoxy-4,5-epoxymorphinan derivatives.

Authors:  L Stavitskaya; A Coop
Journal:  Mini Rev Med Chem       Date:  2011-10       Impact factor: 3.862

4.  Structural determinants of opioid and NOP receptor activity in derivatives of buprenorphine.

Authors:  Gerta Cami-Kobeci; Willma E Polgar; Taline V Khroyan; Lawrence Toll; Stephen M Husbands
Journal:  J Med Chem       Date:  2011-09-07       Impact factor: 7.446

5.  Structural determinants of opioid activity in derivatives of 14-aminomorphinones: effects of changes to the chain linking of the C14-amino group to the aryl ring.

Authors:  David Rennison; Humphrey Moynihan; John R Traynor; John W Lewis; Stephen M Husbands
Journal:  J Med Chem       Date:  2006-10-05       Impact factor: 7.446

6.  Putative irreversible inhibitors of the human sodium-dependent bile acid transporter (hASBT; SLC10A2) support the role of transmembrane domain 7 in substrate binding/translocation.

Authors:  Pablo M González; Naissan Hussainzada; Peter W Swaan; Alexander D Mackerell; James E Polli
Journal:  Pharm Res       Date:  2012-02-22       Impact factor: 4.200

7.  14 beta-O-cinnamoylnaltrexone and related dihydrocodeinones are mu opioid receptor partial agonists with predominant antagonist activity.

Authors:  H Moynihan; A R Jales; B M Greedy; D Rennison; J H Broadbear; L Purington; J R Traynor; J H Woods; J W Lewis; S M Husbands
Journal:  J Med Chem       Date:  2009-03-26       Impact factor: 7.446

8.  Activities of mixed NOP and mu-opioid receptor ligands.

Authors:  B Spagnolo; G Calo; W E Polgar; F Jiang; C M Olsen; I Berzetei-Gurske; T V Khroyan; S M Husbands; J W Lewis; L Toll; N T Zaveri
Journal:  Br J Pharmacol       Date:  2007-12-03       Impact factor: 8.739

9.  Orvinols with mixed kappa/mu opioid receptor agonist activity.

Authors:  Benjamin M Greedy; Faye Bradbury; Mark P Thomas; Konstantinos Grivas; Gerta Cami-Kobeci; Ashley Archambeau; Kelly Bosse; Mary J Clark; Mario Aceto; John W Lewis; John R Traynor; Stephen M Husbands
Journal:  J Med Chem       Date:  2013-04-03       Impact factor: 7.446
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.